{"id":"W4286602972","doi":"10.1200/jco.22.00221","title":"Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital; University of Toronto; University Health Network; McGill University; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Gastroenterology; Lenvatinib; Phases of clinical research; Oncology; Immunotherapy; Toxicity; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002033741,0.001875914,0.001396123,0.0003922851,0.0003704777,0.001158165,0.001077145,0.001279802,0.006606599],"category_scores_gemma":[0.0008311353,0.0007014514,0.001025522,0.0003414333,0.0007252089,0.0008201943,0.0003829927,0.003453854,0.001664503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001131303,"about_ca_system_score_gemma":0.001883387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007531899,"about_ca_topic_score_gemma":0.001791666,"domain_scores_codex":[0.9995066,0.000283833,0.00001952607,0.00007586416,0.00005462384,0.00005954726],"domain_scores_gemma":[0.9995441,0.00007715543,0.0001130148,0.00003366469,0.00003778322,0.0001943029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7404448,0.07785,0.007645525,0.001865949,0.002811882,0.0003994737,0.0002892911,0.003737605,0.03678572,0.0006912707,0.01196965,0.1155087],"study_design_scores_gemma":[0.7848827,0.1974268,0.007339579,0.00006402207,0.0004400863,0.0003201696,0.00004083482,0.001521253,0.002522561,0.000252609,0.00516444,0.00002496094],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716861,0.004661035,0.001540495,0.00107975,0.0002644537,0.01031546,0.003917583,0.0002562299,0.00627894],"genre_scores_gemma":[0.9699526,0.002549407,0.003335538,0.001764315,0.0002047821,0.008643208,0.005545624,0.00005502745,0.007949446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006606599,"threshold_uncertainty_score":0.02210128,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1226614338516699,"score_gpt":0.4658847024227313,"score_spread":0.3432232685710614,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}